Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma

NCT00498836 is registered in ClinicalTrials.gov with Clavis Pharma as lead sponsor.

NCT NCT00498836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00498836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma
Lead sponsor
Clavis Pharma
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
October 31, 2008
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma